gammaPGA Conjugates for Eliciting Immune Responses Directed Against Bacillus anthracis and Other Bacilli


This invention claims immunogenic conjugates of a poly-gamma-glutamic acid (gammaPGA) of B. anthracis, or of another bacillus that expresses a gammaPGA that elicit a serum antibody response against B. anthracis, in mammalian hosts to which the conjugates are administered. The invention also relates methods which are useful for eliciting an immunogenic response in mammals, particularly humans, including responses which provide protection against, or reduce the severity of, infections caused by B. anthracis. The vaccines claimed in this application are intended for active immunization for prevention of B. anthracis infection, and for preparation of immune antibodies. The vaccines of this invention are designed to confer specific immunity against infection with B. anthracis, and to induce antibodies specific to B. anthracis gammaPGA. The B. anthracis vaccine is composed of non-toxic bacterial components, suitable for infants, children of all ages, and adults.

Inventors:

Rachel Schneerson (NICHD)  ➽ more inventions...

Joseph Shiloach (NIDDK)  ➽ more inventions...

Darrell Liu (NICHD)  ➽ more inventions...

Joanna Kubler-kielb (NICHD)  ➽ more inventions...

Fathy Majadly (NICHD)  ➽ more inventions...

Stephen Leppla (NIDCR)  ➽ more inventions...

John Robbins (NICHD)  ➽ more inventions...


Intellectual Property:
U.S. Pat: 7,803,386 issued 2010-09-28
US Application No. 10/559,825
PCT Application No. PCT/US2004/17736

Publications:
Schneerson R, et al. PMID 12857944

Licensing Contact:
Martha Lubet, Ph.D.
Email: lubetm@mail.nih.gov
Phone: 240-276-5508

OTT Reference No: E-343-2002-0
Updated: May 4, 2018